close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vividion Therapeutics, Inc.

News headline image
Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics to Expand with New Global Research and Development Center
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2022’ Award Winner by the San Diego Union-Tribune
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Announces Formation of Scientific Advisory Board
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Appoints Christine Siu to Board of Directors
From Vividion Therapeutics, Inc.
Via Business Wire
News headline image
Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
From Vividion Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today